NIKKEI 225
27,772.93 +305.70 (+1.11%) HANG SENG
24,952.35 +824.50 (+3.42%) CRUDE OIL
86.29 -0.67 (-0.77%) GOLD FUTURES
1,839.80 -3.40 (-0.18%) DOW
34,715.39 -313.26 (-0.89%) BTC-GBP
30,455.78 -502.65 (-1.62%)
Syros Pharmaceuticals, Inc. (0LC7.L)
| Previous close | 3.35 |
| Open | 2.85 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 2.85 - 2.85 |
| 52-week range | 2.85 - 2.85 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 1.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.57 |
| Earnings date | 02 Mar 2022 - 07 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
CAMBRIDGE, Mass., January 10, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its clinical development programs and outlined its strategic priorities and upcoming expected milestones.
- Simply Wall St.
Here's Why Syros Pharmaceuticals (NASDAQ:SYRS) Can Manage Its Debt Despite Losing Money
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Business Wire
Syros to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., November 16, 2021--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will also be available for one-on-one meetings.
